Coronary Physiology in epicardial coronary syndrome (including difference between NHPR and FFR)

Dr. Ozan Demir is a Structural and Interventional Cardiology Fellow at Hammersmith Hospital London. He recently completed post as Clinical Research Fellow at St Thomas’ Hospital and King’s College London, where he is undertook a PhD in coronary physiology under the supervision of Professor Divaka Perera. He studied Medicine at King’s College London and trained in London prior to undertaking Interventional Cardiology Fellowships at Hammersmith Hospital, London and San Raffaele, Milano. During his Fellowship in Milano, under the supervision of Professor Antonio Colombo and Professor Azeem Latib, he undertook an MSc in Interventional Cardiology at the Università Vita-Salute San Raffaele. He is currently involved in various clinical research studies on cardiovascular physiology.

Asst. Prof. Pawel Gasior is an interventional cardiology fellow in Division of Cardiology and Structural Heart Diseases, Medical University of Silesia in Poland. He is a Fellow of the European Society of Cardiology and the currently act as co-chair of the EAPCI New Initiatives for Young Interventionalists Committee. Following graduation from Medical University of Silesia he undertook research fellowship at Cardiovascular Research Foundation in New York under supervision of Dr. Juan Granada. Besides clinical medicine, he is also engaged in both clinical and preclinical research on intravascular imaging, new intravascular technologies, coronary physiology and coronary artery disease.

Professor Rajesh Kharbanda is a Consultant Cardiologist Oxford University Hospitals, UK with over 20 years of experience in treating patients with a wide range of heart conditions including angina, valve disease, heart failure and irregular heart rhythm. He has special expertise in the treatment of coronary artery disease by coronary angioplasty and stenting including complex angioplasty techniques as well as Structural Heart interventions. He has published and co-authored over 240 scientific papers in peer-reviewed journals and actively involved in international trials evaluating various coronary and transcatheter valve technologies.